

# Carbon Reduction Plan

**Supplier name:** Macure Pharma UK Ltd

**Publication date:** 2<sup>nd</sup> August 2024

## Commitment to achieving Net Zero

Macure Pharma UK Ltd is committed to achieving Net Zero emissions by 2050.

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

<b>Baseline Year: 2023</b>	
<b>Additional Details relating to the Baseline Emissions calculations.</b>	
We are reporting only 2023 data this year, as it is our first year of reporting our emissions. Therefore, the reported emissions from 2023 serve as our baseline emissions for future reported emissions.	
<b>Baseline year emissions:</b>	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1<sup>1</sup></b>	<b>0</b>
<b>Scope 2<sup>2</sup></b>	<b>0.05</b>
<b>Scope 3 (Included Sources)</b>	<b>4,832</b> <b>Includes the following Scope 3 source categories:</b> 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business travel 7. Employee commuting 9. Downstream transportation and distribution
<b>Total Emissions</b>	<b>4,832.05</b>

<sup>1</sup> Macure Pharma UK Ltd has no direct emissions from its operations in the UK. All reported emissions are categorized under Scope 2 and Scope 3.

<sup>2</sup> Scope 2 emissions originate from our WeWork London office space, calculated using the location-based method.

## Current Emissions Reporting

Reporting Year: 2023 (January 1 <sup>st</sup> 2023 to December 31 <sup>st</sup> 2023)	
EMISSIONS	TOTAL (tCO <sub>2</sub> e)
Scope 1 <sup>3</sup>	0
Scope 2 <sup>4</sup>	0.05
Scope 3 (Included Sources)	<b>4,832</b> <b>Includes the following Scope 3 source categories:</b> <ul style="list-style-type: none"> <li>4. Upstream transportation and distribution</li> <li>5. Waste generated in operations</li> <li>6. Business travel</li> <li>7. Employee commuting</li> <li>9. Downstream transportation and distribution</li> </ul>
<b>Total Emissions</b>	<b>4,832.05</b>

## Emissions Reduction Targets

We are committed to achieving Net Zero emissions by 2050. This year, we report only 2023 data (the “base year” data), therefore, no graph is available to show progress.

## Carbon Reduction Initiatives

This is the first time Macure Pharma UK Ltd is reporting on its Carbon Reduction Plan, in alignment with our Net Zero ambition for 2050.

*Planned initiatives include:*

- We want to collaborate with our transportation partners to optimise logistics through route optimisation and consolidating shipments, opting for an electrified fleet, and encourage working towards green certificates for sustainable logistics. We would like to track the carbon emissions data more closely and encourage our transportation partners to actively monitor their overall carbon footprint.

<sup>3</sup> Macure Pharma UK Ltd has no direct emissions from its operations in the UK. All reported emissions are categorized under Scope 2 and Scope 3.

<sup>4</sup> Scope 2 emissions originate from our WeWork London office space, calculated using the location-based method.

- For product transparency, we aim to thoroughly map all our product components to transition to eco-friendly alternatives, including primary, secondary, and tertiary packaging. This requires close collaboration with our suppliers and sub-suppliers involved in the manufacturing processes.
- To increase the likelihood of obtaining certification by recognised standards and regulations in the future, we are laying the groundwork for sustainability and environmental considerations.

### **Declaration and Sign Off**


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>5</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>6</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>7</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

### **Signed on behalf of Macure Pharma UK Ltd**



.....

Full name: Lars Mark Poulsen  
Position: Director & Owner

Date: 2<sup>nd</sup> August 2024

---

<sup>5</sup><https://ghgprotocol.org/corporate-standard>

<sup>6</sup><https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

<sup>7</sup><https://ghgprotocol.org/standards/scope-3-standard>